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Abstract
The manufacture of large quantities of high-quality DNA is a major bottleneck in the production of viral vectors for gene
therapy. Touchlight Genetics has developed a proprietary abiological technology that addresses the major issues in
commercial DNA supply. The technology uses ‘rolling-circle’ ampliﬁcation to produce large quantities of concatameric
DNA that is then processed to create closed linear double-stranded DNA by enzymatic digestion. This novel form of DNA,
Doggybone™ DNA (dbDNA™), is structurally distinct from plasmid DNA. Here we compare lentiviral vectors production
from dbDNA™ and plasmid DNA. Lentiviral vectors were administered to neonatal mice via intracerebroventricular
injection. Luciferase expression was quantiﬁed in conscious mice continually by whole-body bioluminescent imaging. We
observed long-term luciferase expression using dbDNA™-derived vectors, which was comparable to plasmid-derived
lentivirus vectors. Here we have demonstrated that functional lentiviral vectors can be produced using the novel dbDNA™
conﬁguration for delivery in vitro and in vivo. Importantly, this could enable lentiviral vector packaging of complex DNA
sequences that have previously been incompatible with bacterial propagation systems, as dbDNA™ technology could
circumvent such restrictions through its phi29-based rolling-circle ampliﬁcation.
Introduction
Lentiviral vectors provide important advantages in gene
therapy applications, such as a large transgene-carrying
capacity [1] and the ability to transduce dividing and non-
dividing cells [2]. Despite the development of packaging
and producer cell lines, lentivirus vectors are predominantly
manufactured by transient transfection of HEK293T cells
with plasmid DNA (pDNA) cassettes encoding the vector
genome, HIV-1 structural proteins and trans-acting factors.
These pDNAs are required at a sizeable manufacturing scale
and represent a signiﬁcant bottleneck to ﬂexible clinical
programmes.
There are several drawbacks associated with bio-
production of lentivirus vector titres on a pDNA platform.
GMP pDNA manufacture is costly, complex and the DNA
product is ultimately contaminated with bacterial propaga-
tion elements that are unnecessary for virus production in
mammalian cells. Furthermore, eukaryotic expression cas-
settes may occasionally contain gene sequences that pro-
duce toxic or problematic effects in bacteria, which limits
their ampliﬁcation.
Touchlight’s novel, synthetic in vitro ampliﬁcation pro-
cess is capable of producing GMP DNA to multi-gram scale
in 2 weeks (WO 2010/086626 5 August 2010). The process
uses rolling-circle ampliﬁcation by phi29 polymerase to
produce long concatameric repeats of the template DNA
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[3]. These concatamers are subsequently reduced to indi-
vidual closed linear DNA molecules called Doggybone™
DNA (dbDNA™) through the action of the protelomerase
enzyme TelN [3]. The process is high-ﬁdelity (1/106–1/107),
highly processive (approximately 70 kbp) and has the added
beneﬁt of being capable of amplifying complex DNA
sequences, without loss of ﬁdelity or yield [4]. The
dbDNA™ is minimal, containing only the user-deﬁned
sequences of interest, with no antibiotic resistance gene or
origin of replication. This has implications for the induction
of immune stimulation effects [5] both in vitro [6] and
in vivo [7]. Thus dbDNA™ potentially offers a safer, more
clinically relevant DNA construct for use in virus manu-
facturing. We have previously observed that, unlike pDNA
containing bacterial elements, dbDNA™ does not evoke
recognition by TLR9 [7–10].
Here we investigated whether lentivirus vectors could be
produced using dbDNA™. We demonstrate that lentiviral
vectors can be produced using all combinations of
dbDNA™ and pDNA in a three-component production
system. Importantly, we show that vectors derived solely
using dbDNA™ constructs produce comparable transgene
expression to plasmid-derived lentivirus vectors in vitro and
titre-matched vectors demonstrated similar transgene
expression in vivo.
Results
Synthesis of dbDNA™ lentivirus vector payload
dbDNA™ was synthesised, as previously described [9],
using a proTLx-K template plasmid derived from a lenti-
virus backbone containing codon-optimised ﬁreﬂy lucifer-
ase under transcriptional regulation of the spleen focus-
forming virus promoter (SFFV), linked to green ﬂuorescent
protein (GFP) by a 2A self-cleaving peptide (pLNT-SFFV-
Luc-2A-GFP, Supplementary Figure 1A) [11].
In brief, the lentivirus transgene backbone from pLNT-
SFFV-Luc-2A-GFP (including the long terminal repeats)
was cloned into the Touchlight proTLx-K template plasmid
in between the protelomerase telRL sites. This construct
was ampliﬁed by rolling circle replication using Bacillus
subtilis phage phi29 DNA polymerase, generating long
concatamer repeats. Escherichia coli phage N15 protelo-
merase TelN was used to cleave and join double-stranded
sequences containing a single cassette. Initial ampliﬁcation
used small amounts of pDNA as a template, which, fol-
lowing its selective degradation with restriction enzymes
and exonucleases, was fully degraded, leaving dbDNA™
only. Simple size-based separation removed dNTPs, primer
and enzymes while facilitating buffer exchange. This
process takes 4–5 days and is then followed by an external
quality control, which is 1 working week.
In vivo transgene expression from payload
dbDNATM
To determine whether the payload dbDNA™ construct was
capable of mediating gene expression, we delivered it
in vivo by hydrodynamic injection into the tail vein of adult
mice as previously described [12].
The following constructs were administered; two plas-
mid constructs, pLNT-SFFV-Luc-2A-GFP and proTLx-K
SFFV-Luc-2A-GFP, and the doggybone construct db-
SFFV-Luc-2A-GFP (Supplementary Figure 1). The
proTLx-K SFFV-Luc-2A-GFP construct is a matched con-
trol to the dbDNA™ construct, containing the telR/L
sequences ﬂanking the gene expression cassette.
Whole-body bioluminescence imaging revealed that
luciferase expression from the dbDNA™ construct was
signiﬁcantly greater at each imaging time point than from
the plasmid and proTLx-K payload constructs (Fig. 1).
Vector production using different combinations of
plasmid and dbDNA™
Lentiviral vectors were produced using different combina-
tions of dbDNA™ and pDNA encoding payload, envelope
Fig. 1 Luciferase expression quantiﬁed from Hydrodynamic injections
of DNA. Plasmid, proTLx-K and dbDNA™ constructs were molarity
matched and administered to 6-week-old mice by hydrodynamic
injections via the tail vein (n= 5 for proTLx-K and dbDNA™ con-
structs and n= 4 for plasmid construct). The expression of luciferase
was quantiﬁed post injection. Luciferase expression from dbDNA™
was consistently signiﬁcantly higher than from plasmid DNA
(repeated-measures analysis of variance with Dunnett’s post hoc test);
luciferase expression from proTLx-K was similar to that from plasmid.
Individual mice are plotted
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and packaging sequences to determine whether components
required for vector production could be supplied by using
the dbDNA™ constructs. The VSV-G envelope protein
used in this vector has a broad tissue tropism [13].
Each lentiviral vector was quantiﬁed by three methods:
p24 enzyme-linked immunosorbent assay (ELISA), ﬂuor-
escence activated cell sorting (FACS) analysis, and quan-
titative polymerase chain reaction (qPCR). p24 ELISA
reveals the total number of viral particles per ml, FACS
analysis measures the number of transducing units per ml,
and qPCR detects the reverse-transcribed viral genome copy
number per ml. The plasmid templates (proTLx-K con-
structs) that were used to synthesise the dbDNA™ were
also used to produce lentiviral vectors as a control (Sup-
plementary Table 1B), as these constructs not only contain
the same sequence as the dbDNA™ constructs but also
have all the elements required for plasmid propagation in
bacteria.
We demonstrate that lentiviral vectors could be produced
using all combinations of dbDNA™ and comparable titres
were obtained for each DNA format (six separate vector
batches) (Fig. 2). Figure 3 shows the titres achieved in three
separate experiments. The results revealed that both sets of
constructs generated good titres of lentiviral vector. The
titres of the dbDNA™ encoded vectors were signiﬁcantly
lower than the plasmid equivalents in the p24 assay (P <
0.001) but there was no difference by FACS or qPCR.
In vitro comparison of transgene expression from
pDNA or dbDNA™ vectors
To examine the transduction efﬁciencies of lentiviral vec-
tors produced by either plasmid or dbDNA™, a dose
escalation of each vector was applied to HEK 293T cells.
Seventy-two hours after transduction, FACS analysis was
conducted, revealing that plasmid and dbDNA™ lentiviral
vectors produced a similar dose–response, as seen by
plotting the percentage of GFP-positive cells vs the mean
ﬂuorescence intensity (MFI) (Fig. 4). However, comparing
the lowest 3 doses, we observed that plasmid lentiviral
vectors give rise to ~2-fold higher percentage of GFP-
positive cells and MFI than dbDNA™ lentiviral vectors.
In vivo validation of titred matched plasmid vs
dbDNA™ lentiviral vectors
Neonatal mice received a dose-matched intracerebroven-
tricular injections of lentiviral vectors produced by either
dbDNA™ or plasmid templates, with doses matched by
either p24 titre (viral particles) or FACS titre (transducing
units). The vectors were administered to P1 neonatal mice
by intracranial injection, as described previously [14].
Luciferase expression was quantiﬁed by whole-body
bioluminescence imaging over the course of development
(Fig. 5a).
There was no signiﬁcant difference in luciferase
expression between the two vectors in vivo with p24 mat-
ched virus, P= 0.43, 3 mice per group (Fig. 5b). We
repeated this experiment with vector titres matched as per
FACS titre where, again, we observed no signiﬁcant dif-
ference in luciferase expression P= 0.33, 3 mice per group
(Fig. 5c).
Discussion
In this report, we have described the ability of dbDNA™
constructs to generate functional lentiviral vectors with
Fig. 3 Comparison of titres between lentiviral vectors produced from
plasmid and dbDNA™. Lentiviral vector produced from plasmid had a
signiﬁcantly higher titre than that produced from dbDNA™ when
titred using p24 and quantitative polymerase chain reaction assay but
not by ﬂuorescence activated cell sorting (two-way analysis of var-
iance with Sidak’s post hoc test)
Fig. 2 Summary of titration values for all lentiviral vectors produced.
Lentiviral vectors using a combination of plasmid and dbDNA™
(payload, packaging and envelope DNA) constructs were titred by
p24, ﬂuorescence activated cell sorting and quantitative polymerase
chain reaction analysis
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comparable in vivo transduction efﬁciency to those pro-
duced with plasmid constructs. From envelope, packaging
and payload templates, it was possible to generate 1.5 mg/ml
of payload, 2.6 mg/ml of envelope and 1.5 mg/ml of
packaging DNA.
Hydrodynamic injection of pDNA was ﬁrst reported by
Liu et al. [15]. Here we observed signiﬁcantly higher
expression from dbDNA™ after a single injection,
approximately 6-fold greater than pDNA 8 weeks after
injection. This is consistent with the work of Lu and col-
leagues [16], where transcriptional silencing was observed
with constructs containing >1 kb of DNA outside of the
expression cassette. In our dbDNA™ constructs, 6.9 kb
exists between the expression cassette and the 5’ and 3’
loops, respectively. An alternative explanation that TelN
sequences confer persistence of expression can be dis-
regarded, since proTLx-K plasmid does result in expression
signiﬁcantly higher than the original payload plasmid.
Indeed, these data warrant further investigation into the
mechanism for enhanced dbDNA™ expression in vivo, in
future studies.
The primary aim of our experiment was to validate
expression from the dbDNA™ payload construct. Impor-
tantly, our data demonstrate that production of functional
lentiviral vectors using dbDNA™ can be achieved, with
transgene expression levels comparable to those of plasmid-
derived vectors.
We consequently tested these vectors in vivo by titre-
matching the plasmid and dbDNA™ lentivirus based on
p24 and FACS titration methods. The vectors were admi-
nistered to neonatal mice via intracerebroventricular injec-
tions and luciferase expression was monitored over the
course of development. These novel ﬁndings revealed a
similar trend in expression from both plasmid and
dbDNA™ titre-matched lentiviral vectors. Although vector
generated from pDNA was signiﬁcantly higher than that
generated by dbDNA™, it is important to note that we did
not optimise PEI:DNA ratios for dbDNA™.
The use of an enzymatic DNA ampliﬁcation platform to
produce constructs for lentivirus production has a number
of potential key advantages, namely speed of production,
cost of goods, elimination of bacterial sequences (such as
origins of replication and antibiotic selection markers) and
avoidance of carry-over of bacterial contaminants (such as
lipopolysaccharide). However, a key advantage of
dbDNA™ arises in its ability to amplify sequences that are
difﬁcult to propagate in bacteria, due to sequence toxicity or
complexity. A number of therapeutically meaningful
transgenes have been identiﬁed as being toxic to bacteria,
including some sodium ion channels [17] and calcium
channels [18]. The use of an enzymatic DNA ampliﬁcation
technology might therefore provide an important platform
for the investigation and therapeutic development of can-
didates for diseases related to these transgenes. It would be
useful to interrogate whether there is any difference in
inﬂammatory and immune markers between plasmid- and
dbDNA™-produced lentivirus vectors. We conducted the in
vivo validation using neonatal mice, which, unlike adult
mice, develop immune tolerance to vectorised transgenes
[19, 20] and are immunologically ignorant to vector com-
ponents [21]. It would be interesting to analyse the potential
beneﬁts for reduced inﬂammatory and immune markers in
adult animals in future studies.
In summary, in this study we were able to show for the
ﬁrst time the production of lentiviral vectors using DNA
constructs produced by enzymatic ampliﬁcation. The
in vitro and in vivo readouts were comparable with our
traditional plasmid-produced lentiviral vectors, despite the
utilisation of systems not optimised for the differing
topology of dbDNA™ compared to plasmid. This platform
could represent a signiﬁcant advance for the development of
gene therapies for previously intractable diseases limited by
difﬁculty in manipulation of pDNA.
Material and methods
dbDNA™ production
Required sequences of the lentivirus payload, envelope and
packaging plasmids were sub-cloned into the proTLx-K
template plasmid inside the protelomerase telR/L sequen-
ces. Veriﬁcation of correct clones was done by Sanger
sequencing.
The template plasmids were denatured using 0.1 M
NaOH for 5 min at 30 °C followed by quenching in reaction
buffer (30 mM Tris–HCl pH 7.4, 5 mM (NH4)2SO4, 30 mM
Fig. 4 In vitro comparison of dbDNA™ and plasmid lentiviral vectors.
Mean ﬂuorescence intensity correlated equally with green ﬂuorescent
protein (GFP)-positive cells for vector generated by both dbDNA™
and plasmid vector
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KCl, 7.5 mM MgCl2, 2 mM dithiothreitol) containing 50
μM custom primer (Metabion, Germany), 4 mM dNTPs
(Bioline, London, UK), 200 units/ml Phi29 polymerase
(Enzymatics, Manchester, UK) and 0.05 units/ml pyr-
ophosphatase (Enzymatics). The reaction was incubated at
30 °C for 30 h and the resulting concatameric DNA pro-
cessed by addition of 2 mM TelN protelomerase (Enzy-
matics). Additional processing was performed using
200 units/ml restriction enzyme suitable for plasmid back-
bone cleavage (template dependent) (Enzymatics or New
England Biolabs, Hitchin, UK) and 200 units/ml exonu-
clease ExoIII (Enzymatics). The dbDNA™ was puriﬁed
from the reaction components by addition of 500 mM NaCl/
100 mM MgCl2 and precipitated using 3.9% polyethylene
glycol (PEG) 8000 (Applichem, Bredbury, UK). dbDNA™
was pelleted (10 min, 4500 g) and re-suspended in 20 ml
500 mM NaCl/100 mM MgCl2. The 3.9% PEG 8000 pre-
cipitation was repeated with ﬁnal resuspension in water
prior to ethanol precipitation to remove residual salts.
Lentiviral vector production
HEK293T cells for viral production were seeded overnight
in a T175-cm2 ﬂask at 2 × 107 cells. Cells were transfected
with 50 µg of payload plasmid or dbDNATM, 17.5 µg of
pMD.G2 (VSV-G envelope plasmids, or VSV-G
dbDNATM) and 32.5 µg of pCMVΔR8.74 (packaging
plasmid and dbDNATM) with 1 µl of polyethylenimine (10
mM) (Sigma-Aldrich, Dorset, UK) in 12 ml of Optimem for
3 h. Media was replaced with fresh Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10% fetal calf serum.
Forty-eight hours after transfection, vector supernatant was
ﬁlter sterilised (0.22 µm) and concentrated by centrifugation
at 5000 rpm for 20 h. The centrifuged viral vector pellet was
resuspended with Optimem and stored at −80 °C.
Titration of vectors
HEK293T cells (2.5 × 105) were seeded into a 96-well plate.
The detection of the enhanced GFP (eGFP) was undertaken
using a BD Verse ﬂow cytometer. eGFP ﬂuorescence was
excited using a 488 nm laser. Analysis of ﬂow cytometry
was conducted as previously described [22]. All ﬂow
cytometric data were analysed by the FlowJo software
version 9.3.1 (Tree Star, Inc).
HEK293T cells (2.5 × 105) were plated into a 24-well
plate and transduced with a range of volumes of con-
centrated lentivirus. Seventy-two hours after transduction,
genomic DNA was extracted and the provirus titre calcu-
lated by qPCR, as described previously [23]. The viral
capsid number was determined using a Lenti-XTM p24
Rapid Titer Kit (Takara, Saint-Germain-en-Laye, France).
The capsid number was determined according to the kit
manufacturer’s calculations and previously described in
Vink et al. [22].
Fig. 5 Whole-body bioluminescence imaging of titre-matched plasmid
and dbDNA™ vector. a Plasmid and dbDNA™ lentiviral vector were
titred matched by either p24 or ﬂuorescence activated cell sorting
(FACS) data. The vectors were administered to neonatal mice via
intracranial administration (n= 3 for each vector). Whole-body bio-
luminescence images were taken every other day. There was no sig-
niﬁcant difference in bioluminescence following injection of either b
p24 titre-matched vectors or c FACS titre-matched vectors. Biolumi-
nescence from individual mice is plotted
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Animal procedures
Outbred CD1 mice used in this study were supplied by
Charles Rivers. All animal experiments conducted within
this study were in agreement with the United Kingdom
Home Ofﬁce guidelines, approved by the ethical review
committee and following the institutional guidelines at
University College London.
Hydrodynamic tail vein injections
Male CD1 mice of 6 weeks of age were used. Mice were
placed in a chamber at 32 °C for 10 min. They were
anaesthetised with isoﬂurane with 100% oxygen (Abbott
Laboratories, London, UK). DNA amounts of 10 µg of
plasmid and proTLx DNA and 7.8 µg of dbDNA™ (to
ensure equal molarity of DNA) made up to 2 ml of
phosphate-buffered saline were injected over approximately
5 s into adult mice.
Neonatal intracerebroventricular injections
For intracerebroventricular injections on the day of birth,
mice were subjected to brief hypothermic anaesthesia fol-
lowed by unilateral injections of concentrated lentiviral
vector (5 µl in total) into the cerebral lateral ventricles using
a 33-gauge Hamilton needle (Fisher Scientiﬁc, Loughbor-
ough), following co-ordinates provided by Kim et al. [24].
Whole-body bioluminescence imaging
Where appropriate, mice were anaesthetised with isoﬂurane
with 100% oxygen and/or received an intraperitoneal
injection of 15 mg/ml of D-luciferin (Gold Biotechnologies,
St. Louis, USA). Mice were imaged after 5 min using a
cooled charged-coupled device camera (IVIS machine,
Perkin Elmer, Coventry, UK) between 1 s and 5 min. The
regions of interest were measured using the Living Image
Software (Perkin Elmer) and expressed as photons
per second per centimetre squared per steradian (photons/
second/cm2/sr).
Statistics
The exact sample sizes of each experimental group/condi-
tion are detailed in the respective legends of each ﬁgure.
The number of replicates is stated in the respective section
of Results. Where possible, two-way analysis of variance
(ANOVA) with the appropriate post hoc test was per-
formed, using GraphPad Prism. ANOVA has been shown to
be robust to non-normal data. Individual plots are provided
for each animal. Exact P values are stated except when the
overall test is not signiﬁcant. The number of replicates was
the minimum possible to address our hypothesis of whether
it was possible to produce lentivirus vectors using
dbDNA™ and if this vector was equivalent, both in vitro
and in vivo, to vector produced using pDNA. No
power calculations were performed. All injected animals
were included in the published analysis. Mice were selected
randomly for injection. Imaging was not performed blind.
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